

# Robert F Spiera

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8575257/publications.pdf>

Version: 2024-02-01

94  
papers

8,780  
citations

94269

37  
h-index

64668

79  
g-index

95  
all docs

95  
docs citations

95  
times ranked

6435  
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to: "Correspondence on "Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement" by Manetti. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e22-e22.	0.5	2
2	New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. <i>Rheumatology</i> , 2022, 61, 2915-2922.	0.9	24
3	Serum Biomarkers of Disease Activity in Longitudinal Assessment of Patients with ANCA-Associated Vasculitis. <i>ACR Open Rheumatology</i> , 2022, 4, 168-176.	0.9	6
4	Systemic sclerosis and COVID-19 vaccines: a SPIN Cohort study. <i>Lancet Rheumatology</i> , The, 2022, 4, e243-e246.	2.2	9
5	Prevalence of frailty in patients with polymyalgia rheumatica and association with health-related quality of life, cognition and sarcopenia. <i>Rheumatology</i> , 2022, 61, 4455-4464.	0.9	2
6	B Cell Reconstitution Is Strongly Associated With COVID-19 Vaccine Responsiveness in Rheumatic Disease Patients Who Received Treatment With Rituximab. <i>Arthritis and Rheumatology</i> , 2022, 74, 776-782.	2.9	14
7	Adipose-Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial. <i>Arthritis and Rheumatology</i> , 2022, 74, 1399-1408.	2.9	9
8	Rho Kinase Expression in Giant Cell Arteritis: Validating pERM Intensity Score to Increase Sensitivity of Temporal Artery Biopsy. <i>Journal of Rheumatology</i> , 2022, , jrheum.220012.	1.0	0
9	Reply. <i>Arthritis and Rheumatology</i> , 2021, 73, 716-717.	2.9	0
10	Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 228-237.	0.5	20
11	Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations. <i>Arthritis Research and Therapy</i> , 2021, 23, 8.	1.6	33
12	Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 469-476.	1.6	23
13	Clinical Manifestations and Long-Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America. <i>ACR Open Rheumatology</i> , 2021, 3, 404-412.	0.9	21
14	Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1357-1359.	0.5	155
15	Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis. <i>JCI Insight</i> , 2021, 6, .	2.3	7
16	A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 131, 124-133.	0.4	1
17	A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 124-133.	0.4	11
18	Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>ACR Open Rheumatology</i> , 2020, 2, 662-671.	0.9	64

#	ARTICLE	IF	CITATIONS
19	Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis. <i>Frontiers in Immunology</i> , 2020, 11, 2053.	2.2	12
20	Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1350-1360.	2.9	67
21	Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis. <i>JCI Insight</i> , 2020, 5, .	2.3	6
22	Arterial lesions in giant cell arteritis: A longitudinal study. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 707-713.	1.6	43
23	The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Journal of Autoimmunity</i> , 2019, 105, 102302.	3.0	24
24	Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 379-398.	0.8	1
25	172. THE ASSOCIATION OF DIFFERENCES IN LIPID PARAMETERS WITH DISEASE ACTIVITY IN ANCA-ASSOCIATED VASCULITIS (AAV). <i>Rheumatology</i> , 2019, 58, .	0.9	0
26	O26 Effects of baseline prednisone dose on remission and disease flare in patients with giant cell arteritis treated with tocilizumab in the GiACTA trial. <i>Rheumatology</i> , 2019, 58, .	0.9	0
27	272 Acute phase reactant levels and prednisone doses at disease flare in patients with giant cell arteritis: prospective data from the GiACTA trial. <i>Rheumatology</i> , 2019, 58, .	0.9	0
28	Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1888-1893.	2.9	25
29	Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1879-1887.	2.9	23
30	Physical or Occupational Therapy Use in Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network Cohort Study. <i>Journal of Rheumatology</i> , 2019, 46, 1605-1613.	1.0	11
31	Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab. <i>Arthritis and Rheumatology</i> , 2019, 71, 1329-1338.	2.9	74
32	OP0069 PERFORMANCE OF AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) COMBINED RESPONSE INDEX IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (CRISS) SCORE IN PHASE 2 TRIAL OF LENABASUM IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSS). , 2019, , .		0
33	FRIO262 CLINICAL OUTCOMES OF PATIENTS WITH GIANT CELL ARTERITIS WITH POLYMYALGIA SYMPTOMS ONLY VS CRANIAL SYMPTOMS ONLY TREATED WITH TOCILIZUMAB OR PLACEBO IN THE GIACTA TRIAL. , 2019, , .		0
34	SAT0284 CD123+ PLASMACYTOID DENDRITIC CELLS (PDCS) FROM SYSTEMIC SCLEROSIS PATIENTS ARE SUSCEPTIBLE TO THE CYTOTOXIC ACTIVITY OF TAGRAXOFUSP, A CD123-TARGETED THERAPY. , 2019, , .		0
35	THU0321 CLINICAL OUTCOMES OF PATIENTS WITH GIANT CELL ARTERITIS AND POLYMYALGIA RHEUMATICA SYMPTOMS TREATED WITH TOCILIZUMAB IN ROUTINE CLINICAL PRACTICE. , 2019, , .		0
36	OP0325 SAFETY AND EFFICACY OF LENABASUM IN AN OPEN-LABEL EXTENSION OF A PHASE 2 STUDY IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS SUBJECTS (DCSSC). , 2019, , .		2

#	ARTICLE	IF	CITATIONS
37	SAT0012â€¦DETECTION OF CIRCULATING PR3-SPECIFIC B CELLS IN PATIENTS WITH ACTIVE ANCA-ASSOCIATED VASCULITIS. , 2019, , .		0
38	Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2018, 70, 1114-1121.	2.9	49
39	Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis. Rheumatology, 2018, 57, 639-650.	0.9	20
40	Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8. Science Translational Medicine, 2018, 10, .	5.8	187
41	Belimumab for the Treatment of Early Diffuse Systemic Sclerosis. Arthritis and Rheumatology, 2018, 70, 308-316.	2.9	98
42	Management of difficult polymyalgia rheumatica and giant cell arteritis: Updates for clinical practice. Best Practice and Research in Clinical Rheumatology, 2018, 32, 803-812.	1.4	3
43	The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. Rheumatology, 2018, 57, 1623-1631.	0.9	53
44	A Randomized, Doubleâ€“Blind Trial of Abatacept (CTLAâ€“4Ig) for the Treatment of Takayasu Arteritis. Arthritis and Rheumatology, 2017, 69, 846-853.	2.9	131
45	A Randomized, Doubleâ€“Blind Trial of Abatacept (CTLAâ€“4Ig) for the Treatment of Giant Cell Arteritis. Arthritis and Rheumatology, 2017, 69, 837-845.	2.9	271
46	Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment. Journal of Rheumatology, 2017, 44, 631-638.	1.0	19
47	Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2017, 69, 1054-1066.	2.9	130
48	Trial of Tocilizumab in Giant-Cell Arteritis. New England Journal of Medicine, 2017, 377, 317-328.	13.9	974
49	Inhibition of $\beta$ -Catenin Signaling in the Skin Rescues Cutaneous Adipogenesis in Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial of C-82. Journal of Investigative Dermatology, 2017, 137, 2473-2483.	0.3	43
50	Comparison of change in end tidal carbon dioxide after three minutes of step exercise between systemic sclerosis patients with and without pulmonary hypertension. Rheumatology, 2017, 56, 87-94.	0.9	2
51	The Pharmacogenomic Association of Fc $\gamma$ 3 Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2017, 69, 169-175.	2.9	21
52	Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis Care and Research, 2017, 69, 1004-1010.	1.5	11
53	Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3â€“Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2017, 69, 185-193.	2.9	45
54	Integration of capillary microscopy and dermoscopy into the rheumatology fellow curriculum. Clinical and Experimental Rheumatology, 2017, 35, 850-852.	0.4	3

#	ARTICLE	IF	CITATIONS
55	Brief Report: A Prospective Open-Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica. <i>Arthritis and Rheumatology</i> , 2016, 68, 2550-2554.	2.9	94
56	Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis. <i>Analytical Chemistry</i> , 2016, 88, 6317-6325.	3.2	24
57	Musculoskeletal Involvement in SSc Is Associated with Worse Scores on Short Form-36 and Scleroderma Health Assessment Questionnaire and Lower Tumor Necrosis Factor- $\alpha$ Gene Expression in Peripheral Blood Mononuclear Cells. <i>HSS Journal</i> , 2016, 12, 255-260.	0.7	3
58	The Recurrence of Digital Ulcers in Patients with Systemic Sclerosis after Discontinuation of Oral Treprostinil. <i>Journal of Rheumatology</i> , 2016, 43, 1665-1671.	1.0	17
59	Myeloperoxidase-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets. <i>Arthritis and Rheumatology</i> , 2016, 68, 2945-2952.	2.9	75
60	Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3. <i>Arthritis and Rheumatology</i> , 2016, 68, 1700-1710.	2.9	132
61	Stress granules and RNA processing bodies are novel autoantibody targets in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2016, 18, 27.	1.6	16
62	Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1166-1169.	0.5	196
63	Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity. <i>JCI Insight</i> , 2016, 1, e89073.	2.3	57
64	Nilotinib (Tasigna, $\oplus$ ) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial. <i>Arthritis Research and Therapy</i> , 2015, 17, 213.	1.6	83
65	A Longitudinal Biomarker for the Extent of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2015, 67, 3004-3015.	2.9	95
66	Pulmonary Vasculitis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 315-331.	0.8	31
67	2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2015, 67, 2569-2580.	2.9	146
68	Increased rho kinase activity in temporal artery biopsies from patients with giant cell arteritis. <i>Rheumatology</i> , 2015, 54, 554-558.	0.9	15
69	Neutrophil-Related Gene Expression and Low-Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2015, 67, 1922-1932.	2.9	116
70	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. <i>American Journal of Human Genetics</i> , 2015, 96, 565-580.	2.6	144
71	2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1799-1807.	0.5	220
72	Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis with Renal Involvement. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 976-985.	3.0	137

#	ARTICLE	IF	CITATIONS
73	Current Landscape of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 1-19.	0.8	19
74	Current Therapies for ANCA-Associated Vasculitis. <i>Annual Review of Medicine</i> , 2015, 66, 227-240.	5.0	24
75	Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2013, 369, 417-427.	13.9	611
76	Biomarkers in ANCA-Associated Vasculitis. <i>Current Rheumatology Reports</i> , 2013, 15, 363.	2.1	13
77	Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1342-1350.	0.5	109
78	Rare Manifestation of Granulomatosis With Polyangiitis. <i>Clinical Advances in Periodontics</i> , 2013, 3, 45-50.	0.4	0
79	Design of the Tocilizumab in Giant Cell Arteritis Trial. <i>International Journal of Rheumatology</i> , 2013, 2013, 1-10.	0.9	96
80	Relationship Between Markers of Platelet Activation and Inflammation with Disease Activity in Wegener's Granulomatosis. <i>Journal of Rheumatology</i> , 2011, 38, 1048-1054.	1.0	45
81	Imatinib and the Treatment of Fibrosis: Recent Trials and Tribulations. <i>Current Rheumatology Reports</i> , 2011, 13, 51-58.	2.1	22
82	Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1003-1009.	0.5	154
83	Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: The Difficulty in Interpreting Proof-of-Concept Studies. <i>International Journal of Rheumatology</i> , 2011, 2011, 1-8.	0.9	6
84	Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2010, 363, 221-232.	13.9	2,275
85	Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis. <i>Annals of Internal Medicine</i> , 2007, 147, 611.	2.0	234
86	ANCA Are Detectable in Nearly All Patients with Active Severe Wegener's Granulomatosis. <i>American Journal of Medicine</i> , 2007, 120, 643.e9-643.e14.	0.6	228
87	Adjunctive methotrexate for treatment of giant cell arteritis: An individual patient data meta-analysis. <i>Arthritis and Rheumatism</i> , 2007, 56, 2789-2797.	6.7	521
88	Therapy for giant cell arteritis: Can we do better?. <i>Arthritis and Rheumatism</i> , 2006, 54, 3071-3074.	6.7	17
89	A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis. <i>Arthritis and Rheumatism</i> , 2005, 52, 902-910.	6.7	43
90	Scleroderma in women with silicone breast implants: comments on the article by Ajñchez-guerrero et al. <i>Arthritis and Rheumatism</i> , 1995, 38, 719-721.	6.7	3

#	ARTICLE	IF	CITATIONS
91	Immunological Reactions to Silicone Implants. <i>BioDrugs</i> , 1994, 1, 406-412.	0.7	4
92	Agreement between physician evaluation and the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS). <i>Arthritis Care and Research</i> , 0, , .	1.5	1
93	Mental Health Care Use and Associated Factors in Systemic Sclerosis: A Scleroderma <scp>Patientâ€Centered</scp> Intervention Network Cohort Study. <i>ACR Open Rheumatology</i> , 0, , .	0.9	0
94	A genomic meta-analysis of clinical variables and their association with intrinsic molecular subsets in systemic sclerosis. <i>Rheumatology</i> , 0, , .	0.9	5